Inventor · disambiguated record
Henry B. Lowman
Also filed as: LOWMAN HENRY · LOWMAN HENRY B · LOWMAN HENRY BERNARD
94 granted patents·75 pending applications·8,651 citations·filing 1991–2025
99Inventor score
Top patents by PatentIndex Score
169 records- 0199US7365166B2Anti-VEGF antibodiesGENENTECH INC·Filed 2006·Granted Apr 29, 2008·90 cites·7 claims
- 0299US7169901B2Anti-VEGF antibodiesGENENTECH INC·Filed 2002·Granted Jan 30, 2007·160 cites·12 claims
- 0399US7060269B1Anti-VEGF antibodiesGENENTECH INC·Filed 2000·Granted Jun 13, 2006·342 cites·2 claims
- 0498US10533053B2Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptorCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 14, 2020·12 cites·20 claims
- 0598US9540440B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Jan 10, 2017·31 cites·25 claims
- 0698US7799900B2Immunoglobulin variants and uses thereofGENENTECH INC·Filed 2005·Granted Sep 21, 2010·103 cites·19 claims
- 0798US7375193B2Anti-VEGF antibodiesGENENTECH INC·Filed 2006·Granted May 20, 2008·62 cites·22 claims
- 0898US5994511AAnti-IgE antibodies and methods of improving polypeptidesGENENTECH INC·Filed 1997·Granted Nov 30, 1999·210 cites·11 claims
- 0998US5849535AHuman growth hormone variantsGENENTECH INC·Filed 1996·Granted Dec 15, 1998·346 cites·22 claims
- 1098US5821047AMonovalent phage displayGENENTECH INC·Filed 1995·Granted Oct 13, 1998·1.2k cites·73 claims
- 1198US5750373AEnrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variantsGENENTECH INC·Filed 1991·Granted May 12, 1998·1.9k cites·50 claims
- 1297US10709799B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·10 cites·31 claims
- 1397US9889211B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Feb 13, 2018·29 cites·52 claims
- 1497US9127053B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 8, 2015·39 cites·33 claims
- 1597US9120853B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 1, 2015·52 cites·43 claims
- 1697US8562992B2Immunoglobulin variants and uses thereofADAMS CAMELLIA W·Filed 2008·Granted Oct 22, 2013·69 cites·6 claims
- 1797US8309300B2Cysteine engineered antibodies and conjugatesJUNUTULA JAGATH REDDY·Filed 2009·Granted Nov 13, 2012·111 cites·6 claims
- 1897US7855275B2Cysteine engineered antibodies and conjugatesGENENTECH INC·Filed 2009·Granted Dec 21, 2010·301 cites·63 claims
- 1997US7521541B2Cysteine engineered antibodies and conjugatesGENENTECH INC·Filed 2005·Granted Apr 21, 2009·1.4k cites·68 claims
- 2097US7435797B2Anti-HER2 antibody variantsGENENTECH INC·Filed 2003·Granted Oct 14, 2008·79 cites·30 claims
- 2197US7297334B2Anti-vegf antibodiesGENENTECH INC·Filed 2004·Granted Nov 20, 2007·112 cites·9 claims
- 2297US6057292AMethod for inhibiting growth hormone actionGENENTECH INC·Filed 1998·Granted May 2, 2000·198 cites·12 claims
- 2396US9545442B2Activatable antibodies that bind epidermal growth factor receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·19 cites·57 claims
- 2496US6632926B1Antibody variantsGENENTECH INC·Filed 1999·Granted Oct 14, 2003·159 cites·3 claims
- 2596US6172213B1Anti-IgE antibodies and method of improving polypeptidesGENENTECH INC·Filed 1998·Granted Jan 9, 2001·155 cites·9 claims
- 2696US5834598AHuman growth hormone variantsGENENTECH INC·Filed 1995·Granted Nov 10, 1998·108 cites·5 claims
- 2796US5534617AHuman growth hormone variants having greater affinity for human growth hormone receptor at site 1GENENTECH INC·Filed 1993·Granted Jul 9, 1996·236 cites·4 claims
- 2895US11180562B2Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodiesCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 23, 2021·5 cites·22 claims
- 2995US10301380B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·17 cites·29 claims
- 3095US9856314B2Activatable antibodies having non-binding steric moieties and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2013·Granted Jan 2, 2018·15 cites·29 claims
- 3195US8372403B2Humanized anti-factor D antibodies and uses thereofGENENTECH INC·Filed 2012·Granted Feb 12, 2013·17 cites·31 claims
- 3295US8067002B2Humanized anti-factor D antibodiesAN LING-LING·Filed 2007·Granted Nov 29, 2011·29 cites·28 claims
- 3394US9517276B2Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2014·Granted Dec 13, 2016·24 cites·31 claims
- 3494US5688666AGrowth hormone variants with altered binding propertiesGENENTECH INC·Filed 1994·Granted Nov 18, 1997·154 cites·28 claims
- 3593US11890354B2Activatable antibodies that bind epidermal growth factor receptor and methods thereofCYTOMX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·2 cites·16 claims
- 3693US9688748B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 27, 2017·11 cites·39 claims
- 3793US8193329B2Nucleic acids encoding anti-factor D antibodiesAN LING-LING·Filed 2011·Granted Jun 5, 2012·15 cites·44 claims
- 3893US7850966B2Method of treating breast cancer using anti-HER2 antibody variantsGENENTECH INC·Filed 2008·Granted Dec 14, 2010·45 cites·54 claims
- 3993US6761889B2Anti-IgE antibodiesGENENTECH INC·Filed 2002·Granted Jul 13, 2004·41 cites·16 claims
- 4093US6022711AHuman growth hormone variants having enhanced affinity for human growth hormone receptor at site 1GENENTECH INC·Filed 1995·Granted Feb 8, 2000·100 cites·8 claims
- 4192US12139543B2Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFRCYTOMX THERAPEUTICS INC·Filed 2021·Granted Nov 12, 2024·1 cites·25 claims
- 4292US8273352B2Humanized anti-factor D antibodies and uses thereofHUANG ARTHUR·Filed 2009·Granted Sep 25, 2012·30 cites·35 claims
- 4392US8187604B2Methods of treating with anti-factor D antibodiesAN LING-LING·Filed 2011·Granted May 29, 2012·12 cites·39 claims
- 4491US8753826B2Methods of detecting factor D with anti-factor D antibodiesGENENTECH INC·Filed 2013·Granted Jun 17, 2014·8 cites·32 claims
- 4591US7432244B2Method of inhibiting insulin-like growth factor-1 (IGF-1) by IGF-1-antagonist peptidesGENENTECH INC·Filed 2006·Granted Oct 7, 2008·16 cites·16 claims
- 4691US6723833B1Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agentGENENTECH INC·Filed 2000·Granted Apr 20, 2004·32 cites·15 claims
- 4791US6682735B2Anti-IgE antibodiesGENENTECH INC·Filed 2001·Granted Jan 27, 2004·30 cites·18 claims
- 4891US6403764B1Insulin-like growth factor-1 protein variantsGENENTECH INC·Filed 2000·Granted Jun 11, 2002·64 cites·3 claims
- 4991US6143523AHuman growth hormone variantsGENENTECH INC·Filed 1995·Granted Nov 7, 2000·84 cites·6 claims
- 5091US2025215094A1Method of using an anti-epidermal growth factor receptor (egfr) activatable antibody to detect the presence or absence of a cleaving agent and egfrCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 169 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Henry B. Lowman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →